SK1-I

SK1-I (BML-258), an analog of sphingosine, is an isozyme-specific competitive SPHK1 inhibitor with a Ki value of 10 μM[1]. SK1-I shows no activity at SPHK1 PKCα, PKCδ, PKA, AKT1, ERK1, EGFR, CDK2, IKKβ or CamK2β. SK1-I enhances autophagy and has antitumor activity[2].

Product Specifications

CAS Number

[1072443-89-0]

Product Name Alternative

BML-258

UNSPSC

12352005

Target

CaMK; SphK

Type

Reference compound

Related Pathways

Immunology/Inflammation; Neuronal Signaling

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/sk1-i.html

Purity

98.83

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

OC[C@H]([C@H](/C=C/C1=CC=C(C=C1)CCCCC)O)NC

Molecular Formula

C17H27NO2

Molecular Weight

277.40

References & Citations

[1]Melissa R Pitman, et al. Inhibitors of the sphingosine kinase pathway as potential therapeutics. Curr Cancer Drug Targets. 2010 Jun;10 (4) :354-67.|[2]Santiago Lima, et al. TP53 is required for BECN1- and ATG5-dependent cell death induced by sphingosine kinase 1 inhibition. Autophagy. 2018;14 (6) :942-957.|[3]Fiona H Greig, et al. Requirement for sphingosine kinase 1 in mediating phase 1 of the hypotensive response to anandamide in the anaesthetised mouse. Eur J Pharmacol. 2019 Jan 5;842:1-9.